Naucleeae

Kratom Watchdog Group Chides News Media for “Blindly” Touting FDA’s “Leafer Madness War” on Coffee-Like Botanical

Retrieved on: 
Tuesday, July 2, 2019
Other Communications, Communications, Public policy, Government, Alternative medicine, Health, Public policy, Other Policy Issues, Psychoactive drugs, Euphoriants, Opioids, Antidiarrhoeals, Mitragyna speciosa, Naucleeae, Health, Watchdog timer, Food and Drug Administration

The FDA announcement about two companies was exploited and turned into a broadside attack in the agencys ongoing Leafer Madness war on kratom, said Max Karlin, spokesperson, Kratom Information & Resource Center.

Key Points: 
  • The FDA announcement about two companies was exploited and turned into a broadside attack in the agencys ongoing Leafer Madness war on kratom, said Max Karlin, spokesperson, Kratom Information & Resource Center.
  • The holiday-themed Kratom Nation initiative asks kratom consumers to talk about their rights and freedoms as they relate to kratom.
  • The Kratom Information & Resource Center is an independent, media watchdog organization devoted to fighting for the truth about kratom.
  • KIRC undertakes research, education and direct one-on-one outreach to promote fair and balanced news coverage of kratom.

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Health, Pharmaceutical, Psychoactive drugs, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Naucleeae, Opioids, Health, Food and Drug Administration, FDA warning letter

The "Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules" newsletter has been added to ResearchAndMarkets.com's offering.
  • The kratom industry is facing continued scrutiny as a contract manufacturer recently received a warning letter from the US FDA, coincidentally made public on the same day the published standards for safety from the American Kratom Association were released.
  • While the FDA warning letter to Avalon Packaging, Inc., a contract manufacturer of kratom, cited issues with manufacturing, including salmonella contamination, the agency refrained referencing its 2017 findings that found kratom constituent ingredients to be opioids and potentially in need of being scheduled as controlled substances by the DEA.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20190626005680/en/

FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses

Retrieved on: 
Tuesday, June 25, 2019
Psychoactive drugs, Euphoriants, Opioids, Antidiarrhoeals, Mitragyna speciosa, Naucleeae, Food and Drug Administration

The companies also make claims about treating pain, as well as other medical conditions like depression, anxiety and cancer.

Key Points: 
  • The companies also make claims about treating pain, as well as other medical conditions like depression, anxiety and cancer.
  • As part of our efforts to assess kratom for contamination in the products tested, we also found high levels of heavy metals in kratom products.
  • There are no FDA-approved uses for kratom, and the agency has received concerning reports about the safety of kratom.
  • The FDA encourages more research to better understand kratom's safety profile, including the use of kratom combined with other drugs.